Qnity is transforming drug discovery with quantum electrochemical sensors that deliver real-time, label-free molecular analysis — faster, smarter, and scalable.
Current Status
● Backed by IP from the University of Oxford and UNESP (State University of Sao Paulo/Brazil).
● $200k early invested by GRIDX, a deeptech venture builder.
● Strategic pilot partnership with Merck KGaA LATAM.
● $1M in non-dilutive grants by early 2026 (PIPE/FAPESP, FINEP) and $75K in early angel capital from global health experts.
● Selected as Top Startup by Atento Capital and George Kaiser Family Foundation to move our HQ to Oklahoma (US) by the end of 2025.
● Recognized as Top Innovator in Quantum (2025) – UpLink by World Economic Forum.
Problem or Opportunity
Drug discovery is slow, risky, and prohibitively expensive, with a single candidate taking up to $60 million and 4–5 years just to reach preclinical validation. Traditional tools fail to adequately detect and assess small molecules, which represent a majority of therapeutically relevant compounds. Furthermore, they lack the real-time, high-resolution precision required to de-risk billion-dollar pharma decisions.
Solution (product or service)
Qnity’s platform uses quantum electrochemistry and custom sensors to detect binding affinity and potentially other critical drug parameters with over 1 million times more sensitivity than current tools, all without labeling. The system offers scalable, plug-and-play deployment, integrates directly with pharmaceutical R&D workflows, and is designed to expand across proteomics, genomics, and metabolomics.
Business model
Qnity is in a pre-revenue stage but is aiming at operating through two synergistic B2B streams:
1. MVP Testing Model
○ Joint development or pilot validation studies, with partners gaining early access to Qnity’s technology in exchange for feedback, visibility, and strategic alignment.
○ Validating the performance and value of its quantum electrochemical sensing platform with strategic partners in the pharmaceutical industry and academic research centers.
2. Razor - Razor Blade Equipment Model
○ Sales of analytical platforms bundled with sensors, software, and support.
